Ruxolitinib Phosphate and Verapamil Immediate-Release Tablets
Determining the interaction of Ruxolitinib Phosphate and Verapamil Immediate-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme. In healthy subjects, administration of a single 10 mg dose of ruxolitinib following pretreatment with the moderate CYP450 3A4 inhibitor erythromycin (500 mg twice daily for four days) resulted in an 8% increase in ruxolitinib peak plasma concentration (Cmax) and a 27% increase in systemic exposure (AUC) compared to administration of ruxolitinib alone. The change in the pharmacodynamic marker, pSTAT3 inhibition, was consistent with the corresponding exposure information. No dosage adjustment is recommended when ruxolitinib is coadministered with mild or moderate CYP450 3A4 inhibitors.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Jakafi (ruxolitinib)." Incyte Corporation, Wilmington, DE.
Generic Name: ruxolitinib
Brand name: Jakafi
Synonyms: Ruxolitinib
Generic Name: verapamil
Brand name: Calan, Isoptin SR, Verelan, Isoptin, Calan SR, Isoptin IV, Covera-HS, Verelan PM
Synonyms: Verapamil
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ruxolitinib Phosphate-Verapamil Injection
- Ruxolitinib Phosphate-Verapamil Intravenous
- Ruxolitinib Phosphate-Verapamil Long-Acting Capsules
- Ruxolitinib Phosphate-Verapamil Long-Acting Tablets
- Ruxolitinib Phosphate-Verapamil oral/injection
- Ruxolitinib Phosphate-Verapamil Sustained-Release Capsules
- Verapamil Immediate-Release Tablets-Ruzurgi
- Verapamil Immediate-Release Tablets-Ryanodex
- Verapamil Immediate-Release Tablets-Rybelsus
- Verapamil Immediate-Release Tablets-Rybix ODT
- Verapamil Immediate-Release Tablets-RyClora
- Verapamil Immediate-Release Tablets-Rydapt